JP2013538040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538040A5 JP2013538040A5 JP2013514398A JP2013514398A JP2013538040A5 JP 2013538040 A5 JP2013538040 A5 JP 2013538040A5 JP 2013514398 A JP2013514398 A JP 2013514398A JP 2013514398 A JP2013514398 A JP 2013514398A JP 2013538040 A5 JP2013538040 A5 JP 2013538040A5
- Authority
- JP
- Japan
- Prior art keywords
- adb
- fiber
- fiber polypeptide
- seq
- multimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 claims description 166
- 229920001184 polypeptide Polymers 0.000 claims description 85
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 66
- 210000000981 epithelium Anatomy 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 102000005707 Desmoglein 2 Human genes 0.000 claims description 17
- 108010045583 Desmoglein 2 Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- 239000000539 dimer Substances 0.000 claims description 9
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 9
- 239000012216 imaging agent Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 206010056375 Bile duct obstruction Diseases 0.000 claims description 2
- 206010004637 Bile duct stone Diseases 0.000 claims description 2
- 206010007882 Cellulitis Diseases 0.000 claims description 2
- 201000009331 Choledocholithiasis Diseases 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 208000001130 gallstones Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000000277 pancreatic duct Anatomy 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 208000014644 Brain disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000013718 rectal benign neoplasm Diseases 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- 206010029098 Neoplasm skin Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 201000011523 endocrine gland cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000025402 neoplasm of esophagus Diseases 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 208000025421 tumor of uterus Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35365210P | 2010-06-10 | 2010-06-10 | |
| US61/353,652 | 2010-06-10 | ||
| US201161430091P | 2011-01-05 | 2011-01-05 | |
| US61/430,091 | 2011-01-05 | ||
| US201161470663P | 2011-04-01 | 2011-04-01 | |
| US61/470,663 | 2011-04-01 | ||
| PCT/US2011/040053 WO2011156761A1 (en) | 2010-06-10 | 2011-06-10 | Methods and systems for adenovirus interaction with desmoglein 2 (dsg2) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176242A Division JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538040A JP2013538040A (ja) | 2013-10-10 |
| JP2013538040A5 true JP2013538040A5 (https=) | 2014-07-24 |
| JP6499825B2 JP6499825B2 (ja) | 2019-04-10 |
Family
ID=45096374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514398A Active JP6499825B2 (ja) | 2010-06-10 | 2011-06-10 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
| JP2016176242A Pending JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016176242A Pending JP2016202188A (ja) | 2010-06-10 | 2016-09-09 | デスモグレイン２（ｄｓｇ２）とのアデノウイルスの相互作用のための方法およびシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8722853B2 (https=) |
| EP (1) | EP2580234B1 (https=) |
| JP (2) | JP6499825B2 (https=) |
| KR (2) | KR20180122043A (https=) |
| AU (1) | AU2011265260C1 (https=) |
| WO (1) | WO2011156761A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013191675A1 (en) * | 2012-06-18 | 2013-12-27 | Empire Technology Development Llc | Ionizing radiation detector for use with endoscopic ultrasound |
| EP2900818B1 (en) | 2012-09-25 | 2017-06-07 | University of Washington through its Center for Commercialization | Desmoglein 2 (dsg2) binding proteins and uses therefor |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| CA2925487C (en) | 2013-09-24 | 2023-11-07 | University Of Washington Through Its Center For Commercialization | Desmoglein 2 (dsg2) binding proteins and uses therefore in treating disorders associated with epithelial tissues |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| IT201600077232A1 (it) * | 2016-07-22 | 2018-01-22 | Bio Optica Milano S P A | Una preparazione liquida acquosa per la conservazione di un campione istologico |
| EP3333176A1 (en) | 2016-12-09 | 2018-06-13 | Universite De Geneve | Peptidic protein kinase c inhibitors and uses thereof |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| US20200347101A1 (en) * | 2018-01-25 | 2020-11-05 | Pai Life Sciences, Inc. | Conjugatable desmoglein 2 (dsg2) binding proteins and uses therefor |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| CN112334150B (zh) | 2018-06-12 | 2025-11-18 | 日内瓦大学 | 肽蛋白激酶c抑制剂及其用途 |
| CN110616199A (zh) * | 2019-06-26 | 2019-12-27 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型重组人7型腺病毒及其制备方法和应用 |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| EP4405372A4 (en) | 2021-09-22 | 2026-01-14 | Hdt Bio Corp | SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE |
| KR20240096468A (ko) | 2021-09-22 | 2024-06-26 | 에이치디티 바이오 코포레이션 | 감염병에 대한 rna 백신 |
| KR20230130804A (ko) * | 2022-03-04 | 2023-09-12 | (주)큐리진 | 순환종양세포 검출을 위한 아데노바이러스 5/3 형 |
| CN115400121B (zh) * | 2022-04-29 | 2023-05-23 | 佛山病原微生物研究院 | 一种snx-2112在制备用于抗腺病毒感染的药物中的用途 |
| CN114652726B (zh) * | 2022-04-29 | 2024-03-19 | 暨南大学 | Biib021在制备预防和/或治疗腺病毒感染的药物中的应用 |
| WO2025081013A1 (en) * | 2023-10-12 | 2025-04-17 | Hdt Bio Corp. | Junction opener protein and nanoparticle compositions and uses thereof |
| CN118421565B (zh) * | 2024-03-21 | 2024-11-29 | 中国人民解放军军事科学院军事医学研究院 | 重组骨软骨干细胞及其制备方法与应用 |
| CN119055642A (zh) * | 2024-07-23 | 2024-12-03 | 湖北工业大学 | Ganetespib化合物在制备抗人类腺病毒7型病毒药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
| IL137730A0 (en) * | 1998-02-17 | 2001-10-31 | Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| EP1141357A1 (en) * | 1999-01-14 | 2001-10-10 | Novartis AG | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| US7560527B1 (en) | 1999-11-25 | 2009-07-14 | Transgene S.A. | Modified adenovirus fibre and uses |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| AU2003249317B2 (en) | 2002-07-19 | 2007-08-02 | Institute Of Materials Research And Engineering | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| US20070104732A1 (en) * | 2003-10-24 | 2007-05-10 | Bernard Massie | Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism |
| KR101539804B1 (ko) | 2008-03-31 | 2015-07-27 | 가부시키가이샤 시세이도 | 폴리실록산, 아크릴계 화합물 및 비닐계 화합물 |
-
2011
- 2011-06-10 KR KR1020187031687A patent/KR20180122043A/ko not_active Withdrawn
- 2011-06-10 AU AU2011265260A patent/AU2011265260C1/en active Active
- 2011-06-10 US US13/158,246 patent/US8722853B2/en active Active
- 2011-06-10 WO PCT/US2011/040053 patent/WO2011156761A1/en not_active Ceased
- 2011-06-10 JP JP2013514398A patent/JP6499825B2/ja active Active
- 2011-06-10 EP EP11736215.2A patent/EP2580234B1/en active Active
- 2011-06-10 KR KR1020137000726A patent/KR101915699B1/ko active Active
-
2013
- 2013-10-29 US US14/066,353 patent/US9200041B2/en active Active
-
2016
- 2016-09-09 JP JP2016176242A patent/JP2016202188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538040A5 (https=) | ||
| RU2016110826A (ru) | Белки, связывающие десмоглеин 2 (dsg2), и их применение | |
| JP2015532265A5 (https=) | ||
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| US12122844B2 (en) | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | |
| JP6144771B2 (ja) | Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物 | |
| JP2016518325A5 (https=) | ||
| JP2014527814A5 (https=) | ||
| RU2018114904A (ru) | Антитело против garp | |
| WO2016106158A1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| JP2013527761A5 (https=) | ||
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| JP2015529641A5 (https=) | ||
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2020526503A5 (https=) | ||
| JP2009518024A5 (https=) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| US20200407420A1 (en) | Her-1, her-3 and igf-1r compositions and uses thereof | |
| ITRM20100577A1 (it) | Immunoterapia contro il recettore erbb-3 | |
| CN104717980A (zh) | 干细胞增强疗法 | |
| JP2010500006A5 (https=) | ||
| CN103561761A (zh) | 用于使用抗-整合素改善抗血管生成疗法的方法和组合物 | |
| Reinacher-Schick et al. | Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies | |
| RU2015154985A (ru) | Способы лечения рака | |
| CN105330739B (zh) | 与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途 |